Revolution Medicines, Inc.
RVMDW· Nasdaq
RVMDWRevolution Medicines, Inc.
Filed Feb 26, 2024 · 10-K · 57 days after period end · 0000950170-24-020145
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022 | Q4 2021 | Q4 2020 |
|---|---|---|---|---|
| Revenue | $742.00K | $7.01M | $7.58M | $8.75M |
| Net Income | -$161.54M | -$68.10M | -$57.65M | -$34.20M |
| EPS Diluted | — | -$0.72 | -$0.78 | -$0.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Feb 26, 2024 · 57 d after period end
